Tagged with BIO

Canada David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…

Switzerland Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL on “Economics of Innovation in the Biomedical Industry”. What are your thoughts on the incorporation of disruptive technologies in the…

Switzerland Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the importance of selecting Switzerland as the location for regional headquarters.   The main challenge in the mature markets is the…

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

India A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar for trastuzumab and the sixth approved biosimilar in the US overall, and how Biocon is implementing a low-value high-volume model…

Switzerland Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”   We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner…

Japan Osamu Nagayama, president of the Japan BioIndustry Association (JBA) and chairman and CEO of Chugai Pharmaceutical, discusses Japan’s footprint in biologics and how mergers between Japanese pharma companies, thereby creating larger R&D funding pools, could hold the key to future success in the biotechnology field. Can you begin by introducing…

Brazil Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA),…

Brazil Luis Eduardo Caroli, CEO of BioZeus, is contributing to the pre-commercial development of Brazilian-born innovations. In this interview he explains how he set up the company and documents the company’s unique model of collaboration between local project managers and highly experienced senior international executives to develop academic science, as well…

Brazil Cristina Dislich Ropke, CEO of Phytobios, a company that helps multinational and local companies turn Brazilian biodiversity into medicinal products, highlights the company’s exceptional perseverance in studying the Brazilian biodiversity at times when legal uncertainties threatened the development of this segment. She also expands on the drug development center founded…

Brazil Roberto Alvarenga, general manager Latin America at Biotronik, the leading company globally for cardiovascular and endovascular medical technologies, documents how he has been leveraging on his long standing experience among prestigious pharmaceutical companies in order to implement pioneering processes in Brazil’s medtech field and ultimately increase Brazilian patients’ access to…